Intellia Therapeutics: Realizing the Dream of Curing Devastating Diseases

Intellia Therapeutics 
Reporting operational highlights and financial results for the second quarter ended June 30, 2020, Intellia Therapeutics (NTLA) announced its first Clinical Trial Application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1 study of NTLA-2001 for transthyretin . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.